Tradestie Institutional Equity Comparison Engine
SRRK vs ELVN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ELVN Overall Edge
ELVN Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Enliven Therapeutics, Inc. Common Stock (ELVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRRK trades at N/M Forward P/E with -71732.3% operating margin (-100.0% YoY revenue) versus ELVN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SRRK sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRRK N/M vs ELVN N/M Fwd P/E
Growth & Margin Winner
ELVN
Op Margin -71732.3% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
ELVN
1Y +43.7% vs +134.5% ยท 52W Pos 43% vs 69%
Options & Structure Winner
ELVN
BREAKDOWN (7th %ile IV) vs CONSOLIDATION (5th %ile IV)
SRRK
NASDAQ
Scholar Rock Holding Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$43.21
+0.01% 1D
Market Cap
$5.3B
1M Return
+8.3%
1Y Return
+43.7%
Forward P/E
N/M
Unified AI Score
55.1 / 100
HOLD
Tech 49.0
Fund 57.0
Flow 64.0
Mom 60.0
ELVN
NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap
$3.6B
1M Return
+27.38%
1Y Return
+134.53%
Forward P/E
N/M
Unified AI Score
36.2 / 100
SELL
Tech 15.0
Fund 44.0
Flow 68.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRRK +43.7%
ELVN +134.53%
Spread: +90.83 pp (ELVN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SRRK TTM Op. Margin: -71732.3%
ELVN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRRK vs ELVN. Trailing 12-month operating profitability (SRRK -71732.3% vs ELVN 0.0%) and valuation multiples (SRRK N/M vs ELVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRRK | ELVN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $5.3B | $3.6B | Larger Scale | SRRK |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | ELVN |
| Operating Margin (TTM) Profitability | -71732.3% | 0.0% | Higher Margin | ELVN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -200.0% | -16.8% | Higher ROE | ELVN |
| 52-Week Range Position Momentum | 43% ($29โ$62) | 69% ($15โ$62) | Stronger Trend | ELVN |
| Beta / 30D Volatility Risk Regime | 1.02ฮฒ ยท 61% Vol | 0.96ฮฒ ยท 60% Vol | Lower Realized Risk | ELVN |
| Unified Institutional Score Composite Signal | 55.1 / 100 (HOLD) | 36.2 / 100 (SELL) | Higher Composite | SRRK |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRRK vs ELVN Buy Guide
SRRK
BREAKDOWN
57d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
7th %ile
IV Regime
Compressed (<25th %ile)
ELVN
CONSOLIDATION
59d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRRK nor ELVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.